SARS-CoV-2 seroprevalence and respiratory disease disability claims in Mexico City Metropolitan Area
David Barros-Sierra, Rodrigo Zepeda‐Tello, Marcela Tamayo‐Ortiz, Héctor Gutiérrez-Díaz, Valeria Aurora Pérez-Chávez, José Antonio de la Rosa-Parra, Luis Enrique Nieto-Barajas, Mauricio Méndez-Aranda, Luis A. Herrera, Mauricio Hernández‐Ávila · Salud Pública de México · 2023
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Salud Pública de México · Instituto Nacional de Salud Pública · article · 2023
Abstract
OBJECTIVE: To characterize the impact of SARS-CoV-2 infection in workers from an essential large-scale company in the Greater Mexico City Metropolitan Area using point prevalence of acute infection, point prevalence of past infection through serum antibodies and respiratory disease short-term disability claims (RD-STDC). MATERIALS AND METHODS: Four randomized surveys, three during 2020 before and one after (December 2021) vaccines' availability.
OUTCOMES: point prevalence of acute infection through saliva PCR (polymerase chain reaction) testing, point prevalence of past infection through serum antibodies against Covid-19, RD-STDC and prevalence of symptoms during the previous six months. RESULTS: Prevalence of SARS-CoV-2 cases was 1.29-4.88%, on average, a quarter of participants pre-vaccination were seropositive; over half of participants with a RD-STDC had antibodies. The odds of having antibodies were 6-7 times more among workers with an RD-STDC. CONCLUSIONS: High antibody levels against Covid-19 in this study population reflects that coverage is high among workers in this industry.
STDCs are a useful tool to track workplace epidemics.
Open the resolved locator · 10.21149/14545
Metadata licence: OpenAlex metadata (CC0)